1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml), TC-3 Gel - Overactive Bladder | Phase 1 / Phase 2 | Withdrawn | UroGen Pharma Ltd. | 2016-10-01 | 2017-06-16 |
Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Lower Urinary Tract Symptoms (1) · Male Urogenital Diseases (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Urinary Bladder Diseases (1) · Urogenital Diseases (1) · Urologic Diseases (1) · Urological Manifestations (1)
Israel (1)
Ifat Klein, PhD (1)